Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 03 Apr 2025 Status changed from active, no longer recruiting to completed.
- 10 Jan 2025 Planned End Date changed from 15 Dec 2024 to 26 Jan 2025.
- 20 Jun 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.